Contemporary treatment standards and trends of systemic therapy in metastatic hormone-sensitive prostate cancer-implementing study data in clinical practice.
The treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) has undergone fundamental changes in recent decades, moving away from the sole use of androgen deprivation therapy (ADT) and towards intensified combination therapies.